SINGAPORE, May 22, 2017 /PRNewswire/ -- DSM Sinochem
Pharmaceuticals (DSP), the global leader in production and
commercialization of sustainable, enzymatic antibiotics, next
generation statins and anti-fungals, announced today that the High
Court of Delhi has granted a
permanent injunction against Sinopharm Weiqida Pharmaceutical for
patent infringement in India.
According to DSM Sinochem Pharmaceuticals' (DSP) wholly owned
subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM
Pharmaceuticals India Pvt. Ltd., the High Court of Delhi, India, has granted a permanent
injunction against Sinopharm Weiqida Pharmaceutical Co., LTD
("Weiqida") for patent infringement of Indian Patent Number
247,301. This patent, which is owned by DSP, relates to amoxicillin
trihydrate having a low free water content and processes for the
manufacture thereof.
The permanent injunction prevents the manufacture, use,
importation, offering for sale and sale of Weiqida's amoxicillin
trihydrate active pharmaceutical ingredient in India, as well as any drug product that
utilizes the active pharmaceutical ingredient.
"DSP welcomes the Court's decision," said Karl Rotthier, CEO at
DSP. "The lawsuit is intended to protect DSP's world class
intellectual property portfolio relating to our innovative,
sustainable, and environmental friendly amoxicillin
technology. DSP will continue to rigorously enforce its IP
assets worldwide as it continues to invest in its innovative
R&D programs directed to enzymatic, sustainable antimicrobials
and statins."
About DSM Sinochem Pharmaceuticals
DSM Sinochem
Pharmaceuticals (DSP) is the global leader in sustainable
antibiotics, next-generation statins and anti-fungals. DSP
develops, produces and sells intermediates, active pharmaceutical
ingredients and drug products. Our employees worldwide work
together to deliver cutting-edge generics solutions that help to
keep customers ahead of the competition.
Headquartered in Singapore, the
group has manufacturing sites and sales offices in China, India,
Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal
DSM, a global science-based company active in health, nutrition and
materials, and Sinochem Group, a Fortune 500 enterprise.
Please visit www.dsm-sinochem.com for more information or
contact
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Global Director Branding &
Communications
E-Mail: communications@dsm-sinochem.com
www.dsm-sinochem.com
Forward-looking statements
This press release may contain forward-looking statements with
respect to DSM Sinochem Pharmaceuticals' (DSP) future (financial)
performance and position. Such statements are based on current
expectations, estimates and projections of DSP and information
currently available to the company. DSP cautions readers that such
statements involve certain risks and uncertainties that are
difficult to predict and therefore it should be understood that
many factors can cause actual performance and position to differ
materially from these statements. DSP has no obligation to update
the statements contained in this press release, unless required by
law. The English language version of the press release is
leading.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dsm-sinochem-pharmaceuticals-wins-indian-patent-infringement-case-against-sinopharm-weiqida-pharmaceutical-300461850.html
SOURCE DSM Sinochem Pharmaceuticals